Using Neuroimaging to Investigate Major Depressive Disorder

Using Neuroimaging to Investigate Neurobiological Correlates of Treatment Resistance Associated With Co-morbid Anxiety in Major Depressive Disorder

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00781677

Enrollment

Registered

2008-10-29

Start date

2008-05-31

Completion date

2011-01-20

Last updated

2019-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Depression, Major Depressive Disorder

Keywords

Major Depressive Disorder, Depression, Anxiety

Brief summary

The purpose of this neuroimaging study is to investigate the brain correlates of Major Depressive Disorder with anxiety symptoms as well as potentially identify predictors of treatment outcome.

Detailed description

The purpose of this study is to test whether the structural and functional connectivity between the dorso-lateral prefrontal cortex (DLPFC) and amygdala will decline as symptoms of co-morbid anxiety (Anxiety Factor Score) increase in patients with MDD. This decrease in connectivity will also account for decrease in treatment response. The structural connectivity will be assessed using Diffusion Tensor Imaging (DTI) and the functional connectivity will be assessed using resting state BOLD fMRI.We propose to use the fMRI and DTI to identify biological markers that are associated with treatment response in a cohort of patients with a spectrum of Anxiety Factor Scores.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* Competent to give informed consent * Diagnosis of Major Depressive Disorder * Males and females * Ages 18-50 years old * All races and ethnicities * Able to read, speak, and understand English\*

Exclusion criteria

* History of psychiatric illness except Major Depressive Disorder, Generalized Anxiety Disorder, Social Phobia, or Specific Phobia * Alcohol or substance abuse within the last 6 months or alcohol or substance dependence within the last year * Diagnosis of an organic brain disease * Serious unstable medical illness * History of serious head injury * Unsafe or unable to have an MRI or previous inability to tolerate MRI * Pregnancy or breast feeding

Design outcomes

Primary

Measure	Time frame
Treatment response-the Quick Inventory of Depressive Symptomatology: Clinician Rated (QIDS-SR)	8 weeks

Secondary

Measure	Time frame
Degree of comorbid anxiety-a subset of the Hamilton Rating Scale for Depression will be used to determine the anxiety/somatization factor scores	8 weeks

Countries

United States

Outcome results